Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals, leading to raised full-year EPS guidance. Despite ongoing NEC baby formula lawsuits ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

Shares of Abbott rose 2% in afternoon trade. Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as ...

Now, medical device companies, including north suburban-based Abbott Laboratories, are hoping health enthusiasts will embrace a new type of wellness accessory: wearable sensors to track glucose ...

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests ...

Abbott stock rose Wednesday after the health care giant narrowly beat Wall Street's third-quarter expectations and raised the midpoint of its earnings outlook. Please watch the video at Investors ...